No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic

被引:36
作者
Schwaiger, Julia [1 ]
Karbiener, Michael [1 ]
Aberham, Claudia [2 ]
Farcet, Maria R. [1 ]
Kreil, Thomas R. [1 ]
机构
[1] Baxter AG, Global Pathogen Safety, Vienna, Austria
[2] Baxter AG, BioLife, Vienna, Austria
关键词
primary immunodeficiency; SARS-CoV-2; SARS coronavirus 2 antibody titer; neutralizing antibodies; COVID-19; intravenous immunoglobulin; plasma; CORONAVIRUS; SERA;
D O I
10.1093/infdis/jiaa593
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
引用
收藏
页码:1960 / 1964
页数:5
相关论文
共 50 条
  • [1] Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic
    Farcet, Maria R.
    Karbiener, Michael
    Schwaiger, Julia
    Ilk, Reinhard
    Kreil, Thomas R.
    JOURNAL OF INFECTIOUS DISEASES, 2021, : 1357 - 1361
  • [2] Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations
    Karbiener, Michael
    Farcet, Maria R.
    Schwaiger, Julia
    Powers, Nicholas
    Lenart, James
    Stewart, Joseph M.
    Tallman, Hema
    Kreil, Thomas R.
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (10) : 1707 - 1711
  • [3] Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
    Maria Diez, Jose
    Romero, Carolina
    Vergara-Alert, Julia
    Bello-Perez, Melissa
    Rodon, Jordi
    Manuel Honrubia, Jose
    Segales, Joaquim
    Sola, Isabel
    Enjuanes, Luis
    Gajardo, Rodrigo
    IMMUNOTHERAPY, 2020, 12 (17) : 1247 - 1255
  • [4] Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
    Tang, Juanjie
    Lee, Youri
    Ravichandran, Supriya
    Grubbs, Gabrielle
    Huang, Chang
    Stauft, Charles B.
    Wang, Tony
    Golding, Basil
    Golding, Hana
    Khurana, Surender
    ISCIENCE, 2021, 24 (09)
  • [5] SARS-CoV-2 infection in China-Before the pandemic
    Liang, Huiying
    Zheng, Lingling
    Xia, Huimin
    Tang, Jinling
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (08): : 1 - 20
  • [6] Advances in Neutralization Assays for SARS-CoV-2
    Lu, Yuying
    Wang, Jin
    Li, Qianlin
    Hu, Huan
    Lu, Jiahai
    Chen, Zeliang
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2021, 94 (03)
  • [7] Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
    Zahra, Fatema Tuz
    Bellusci, Lorenza
    Grubbs, Gabrielle
    Golding, Hana
    Khurana, Surender
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (07) : 1044 - 1045
  • [8] Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
    Maeda, Kenji
    Higashi-Kuwata, Nobuyo
    Kinoshita, Noriko
    Kutsuna, Satoshi
    Tsuchiya, Kiyoto
    Hattori, Shin-ichiro
    Matsuda, Kouki
    Takamatsu, Yuki
    Gatanaga, Hiroyuki
    Oka, Shinichi
    Sugiyama, Haruhito
    Ohmagari, Norio
    Mitsuya, Hiroaki
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency
    Chiang, Chia-Jung
    Hsu, Wei-Lun
    Su, Mei-Tsz
    Ko, Wen-Chien
    Hsu, Keng-Fu
    Tsai, Pei-Yin
    VACCINES, 2024, 12 (02)
  • [10] SARS-CoV-2 and Plasma Hypercoagulability
    Steadman, Elisabeth
    Fandaros, Marina
    Yin, Wei
    CELLULAR AND MOLECULAR BIOENGINEERING, 2021, 14 (05) : 513 - 522